Peptide Therapeutics Market Key Opportunity, Analysis, Growth, Trends 2030

The peptide therapeutics market reached a value of USD 42.05 billion in 2022 and is projected to grow at a CAGR of 6.3% from 2023 to 2030. The increasing prevalence of cancer and metabolic disorders such as osteoporosis, obesity, and diabetes will drive the adoption of peptide therapeutics during the forecast period. There is a high demand for cost-effective drugs due to the growing number of pediatric patients and the pervasiveness of target diseases in low-income countries. Peptide therapeutics are also being explored as treatments for COVID-19, with researchers searching for compounds that can block the mechanisms involved in infection or treat the resulting conditions.

On February 21, 2020, the Food and Drug Administration expanded the definition of biologics to include chemically synthesized polypeptides larger than 40 amino acids but less than 100 amino acids, as well as synthetic peptides with 40 or fewer amino acids. This recognition of peptide drugs as potential COVID-19 treatments is expected to have a positive impact on the market.

The COVID-19 pandemic caused significant disruptions to clinical trials in the United States, affecting the healthcare sector. Many organizations involved in drug research had to relocate to remote working environments, leading to interruptions in non-COVID-19 experiments. Consequently, COVID-19 is expected to have a greater influence on the non-COVID-19 peptide therapeutics market during the global epidemic.

Request Free Sample Report @ https://www.marketdigits.com/request/sample/640

Increased investments in drug discovery are directly contributing to market growth. Peptide therapeutics research and development primarily focuses on oncology, infectious diseases, metabolic disorders, and diabetes. The presence of a strong product pipeline and advancements in peptide manufacturing processes are expected to further drive market growth.

Companies are undertaking initiatives to develop new drug candidates and engage in extensive R&D to maintain their market position. The number of clinical trials for peptide therapeutics has significantly increased over the past decade, propelling growth in the forecast period. Partnerships and collaborations, such as the one between Amgen and Generate Biomedicines, contribute to the development of novel protein therapeutics.

Chronic diseases, including cancer, diabetes, and cardiovascular diseases, are major causes of morbidity and mortality worldwide. The rising prevalence of chronic diseases increases the demand for effective therapeutics, but the market growth may be limited by challenges in peptide therapeutics development, increasing costs, and strict regulatory requirements.

Key Companies and Market Share Analysis
Companies in the market employ strategies such as developing new products and technological advancements to gain a competitive position. Additionally, increasing collaborations for conducting trials of new drugs are expected to intensify competitive rivalry. For example, in March 2023, Ono Pharmaceuticals and PeptiDream announced a collaboration for the discovery and development of Macrocyclic Constrained Peptide Therapeutics.

In May 2022, LOTTE Corporation acquired Bristol Myers Squibb's production plant in East Syracuse, New York, to establish its novel biologics CDMO business in the U.S. In February 2022, Amgen and Plexium, Inc. entered into a research collaboration and license agreement to develop new targeted protein degradation therapeutics. These partnerships leverage the expertise of each company to drive the development of innovative therapeutics.

Request For Discount @ https://www.marketdigits.com/request/discount/640

Global Peptide Therapeutics Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, MarketDigits has segmented the global peptide therapeutics market report based on application, type, type of manufacturer, route of administration, synthesis technology, and region:

Application Outlook (Revenue, USD Billion, 2018 - 2030)
• Cancer
• Metabolic Disorders
• Cardiovascular Disorders
• Respiratory Disorders
• Gastrointestinal Disorders
• Infectious Diseases
• Pain
• Dermatological Disorders
• Neurological Disorders
• Renal Disorders
• Others

Type Outlook (Revenue, USD Billion, 2018 - 2030)
• Generic
• Innovative

Type Of Manufacturers Outlook (Revenue, USD Billion, 2018 - 2030)
• In-house
• Outsourced

Route Of Administration Outlook (Revenue, USD Billion, 2018 - 2030)
• Parenteral Route
• Oral Route
• Pulmonary
• Mucosal
• Others

Synthesis Technology Outlook (Revenue, USD Billion, 2018 - 2030)
• Solid Phase Peptide Synthesis (SPPS)
• Liquid Phase Peptide Synthesis (LPPS)
• Hybrid Technology

Enquire about the report @ https://www.marketdigits.com/request/enquiry-before-buying/640

Contact US:
1248 CarMia Way Richmond,
VA 23235, United States.
Phone: +1 510-730-3200
Email: mailto:sales@marketdigits.com
Website: https://www.marketdigits.com

About MarketDigits:
MarketDigits is one of the leading business research and consulting companies that helps clients to tap new and emerging opportunities and revenue areas, thereby assisting them in operational and strategic decision-making. We at MarketDigits believe that market is a small place and an interface between the supplier and the consumer, thus our focus remains mainly on business research that includes the entire value chain and not only the markets.

We offer services that are most relevant and beneficial to the users, which help businesses to sustain in this competitive market. Our detailed and in-depth analysis of the markets catering to strategic, tactical, and operational data analysis & reporting needs of various industries utilize advanced technology so that our clients get better insights into the markets and identify lucrative opportunities and areas of incremental revenues.

This release was published on openPR.